These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2211440)

  • 21. In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.
    Armstrong ES; Farrell DJ; Palchak M; Steenbergen JN
    Antimicrob Agents Chemother; 2016 Jan; 60(1):666-8. PubMed ID: 26552971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
    Brook I
    J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidrug-resistant Bacteroides fragilis group on the rise in Europe?
    Hartmeyer GN; Sóki J; Nagy E; Justesen US
    J Med Microbiol; 2012 Dec; 61(Pt 12):1784-1788. PubMed ID: 22956754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Evolution of the sensitivity of Bacteroides group fragilis at the Sevilla University Hospital (1983-1987)].
    Borobio MV; Domínguez MC; Pallares JA; Perea EJ
    Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):214-8. PubMed ID: 1863620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transfer of tetracycline or clindamycin resistance among strains of Bacteroides fragilis in experimental abscesses.
    Butler E; Joiner KA; Malamy M; Bartlett JC; Tally FP
    J Infect Dis; 1984 Jul; 150(1):20-4. PubMed ID: 6747344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems.
    Goldstein EJ; Citron DM; Tyrrell KL; Leoncio ES; Merriam CV
    Anaerobe; 2017 Feb; 43():1-3. PubMed ID: 27713022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacteroides fragilis resistant to the administration of clindamycin.
    Salaki JS; Black R; Tally FP; Kislak JW
    Am J Med; 1976 Mar; 60(3):426-8. PubMed ID: 1258888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibiotic sensitivity of the Bacteroides fragilis group in Denmark. Danish Study Group.
    Bremmelgaard A; Jansen JE; Justesen T; Gottschau A
    APMIS; 1993 Sep; 101(9):727-31. PubMed ID: 8240792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A clinical isolate of Bacteroides fragilis from Hungary with high-level resistance to imipenem.
    Sóki J; Edwards R; Urbán E; Fodor E; Nagy E
    J Med Microbiol; 2001 Jan; 50(1):107. PubMed ID: 11192497
    [No Abstract]   [Full Text] [Related]  

  • 30. The in-vitro activity of three long-acting cephalosporins against Bacteroides fragilis, Peptostreptococcus species and Clostridium perfringens.
    Watt B; Naden MG
    J Chemother; 1989 Jul; 1(4 Suppl):106-7. PubMed ID: 16312326
    [No Abstract]   [Full Text] [Related]  

  • 31. Metronidazole and spiramycin in abscesses caused by Bacteroides spp. and Staphylococcus aureus in mice.
    Brook I
    J Antimicrob Chemother; 1987 Nov; 20(5):713-8. PubMed ID: 3429373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.
    Thadepalli H; Gollapudi SV; Chuah SK
    Antimicrob Agents Chemother; 1986 Oct; 30(4):574-6. PubMed ID: 3539011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative antibacterial efficacy of clindamycin and metronidazole against Bacteroides fragilis in vitro and in experimentally infected mice.
    Dijkmans BA; Vaishnav J; Mattie H
    Chemotherapy; 1985; 31(4):297-303. PubMed ID: 4028873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beta-lactamases from Bacteroides fragilis active against oximino-cephalosporins.
    Werner RG; Appel KR; Erne AM
    Arzneimittelforschung; 1985; 35(1A):348-50. PubMed ID: 3872669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
    Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
    Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess.
    Fu KP; Lasinski ER; Zoganas HC; Kimble EF; Konopka EA
    J Antimicrob Chemother; 1984 Dec; 14(6):633-40. PubMed ID: 6520063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbapenem resistance in Bacteroides fragilis.
    Ang L; Brenwald NP; Walker RM; Andrews J; Fraise A
    J Antimicrob Chemother; 2007 May; 59(5):1042-4. PubMed ID: 17363423
    [No Abstract]   [Full Text] [Related]  

  • 38. In-vitro activity of ciprofloxacin combined with flomoxef against Bacteroides fragilis, compared with that of ciprofloxacin combined with clindamycin.
    Kato K; Iwai S; Sato T; Harada T; Nakagawa Y; Iwanaga H; Ito Y; Takayama T
    J Infect Chemother; 2002 Jun; 8(2):190-3. PubMed ID: 12111577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two cases of infections due to multidrug-resistant Bacteroides fragilis group strains.
    Katsandri A; Papaparaskevas J; Pantazatou A; Petrikkos GL; Thomopoulos G; Houhoula DP; Avlamis A
    J Clin Microbiol; 2006 Sep; 44(9):3465-7. PubMed ID: 16954304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods.
    Drasar FA; Farrell W; Howard AJ; Hince C; Leung T; Williams JD
    J Antimicrob Chemother; 1978 Sep; 4(5):445-50. PubMed ID: 308506
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.